Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Safinamide loss of exclusivity?

See the DrugPatentWatch profile for Safinamide

Safinamide (brand name Xadago) – when will it lose exclusivity?

Region Current protection Expected loss of exclusivity Notes
United States 5‑year FDA “new drug” exclusivity (2015‑2020) + 10 patents on the drug substance, formulation and use 2025–2026 (latest patent expiry) The 5‑year exclusivity expired in 2020, but the patents still protect the drug. The earliest FDA approval for a generic is likely when the last patent—most of which are set to expire in 2025—clears the way.
European Union 12‑year product‑specific marketing authorization (2016‑2028) + multiple patents 2028–2030 (depending on region) EU exclusivity lasts until 2028. Patents in the EU expire 2028–2030, so generics could appear after that window.
Canada 10‑year market‑authorization protection (2016‑2026) + patents 2026–2027 Canada’s protection ends in 2026; generics can be launched thereafter if all patents have expired.
Australia 10‑year product‑specific protection (2016‑2026) + patents 2026–2027 Same as Canada; generics likely in 2027.
Other Countries Varies Usually between 2025–2028 Patents and regulatory protection differ by country.

What does “loss of exclusivity” actually mean?

  1. Patent expiry – When the last patent covering the drug (or its formulation) expires, competitors can manufacture the same molecule.
  2. Regulatory approval – Even after a patent expires, a generic company must file an Abbreviated New Drug Application (ANDA) in the U.S. or an equivalent application elsewhere. The FDA (or other regulators) must review and approve the generic, which can take 1–2 years after filing.
  3. Market entry – Once approved, the generic can enter the market. The price usually drops significantly because the brand name loses its pricing advantage.

Current status (as of 2026‑Q1)

  • U.S.: No generic has yet been approved. Several companies (e.g., Teva, Sandoz) have filed ANDAs, but the first approval is expected in 2026 or early 2027 after the last patent expires.
  • EU/Canada/Australia: Similar filings are underway. Generic launch is anticipated 2026–2028, depending on regulatory reviews.

What to expect for patients and payers

Scenario Impact
Brand‑name Xadago remains Continued use of the original drug; no change in cost to the patient or pharmacy.
Generic enters Prices may drop by 50‑80 % (typical for generics). Insurance formularies may switch to the generic automatically.
Patent litigation If a patent dispute arises, the timeline could shift. A successful challenge might accelerate generic entry.

Bottom line

  • Safinamide will lose its last U.S. patent protection in 2025‑2026.
  • Generic approval and launch are expected in 2026 or 2027.
  • In the EU and Commonwealth countries, the timeline is a year or two later (2028‑2030).

If you’re a prescriber or a patient waiting for a generic, keep an eye on FDA announcements and the European Medicines Agency’s “Generic Drugs” portal. That’s the best way to get the latest, official dates.



Other Questions About Safinamide :

Msn safinamide patent? Safinamide? Safinamide brand name? Newron safinamide court?